Our data consolidate these findings with GCB-derived lymphoma cell lines and provide a rationale to treat B-cell lymphoma with low SLFN11 expression by combining tazemetostat with AraC. Here, SLFN11 is linked to B-cell non-Hodgkin lymphoma.